Report
Our reports provide latest industry trends, forecasts, company profiles, competitive landscape, and strategic insights.
Europe Intravenous Immunoglobulin Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Carmine, Anthocyanins, Caramel, Curcumin, Annatto, Carotenoids, Chlorophyll, and Others), Form (Liquid & Gel and Powder), and Application (Bakery and Confectionery, Dairy and Frozen Desserts, Beverages, Sauces; Dressings; and Condiments, RTC and RTE Products, Meat; Poultry and Seafood, and Others)
- Report Code : BMIRE00027587
- Pages : 186
The intravenous immunoglobulin market in Europe is expected to grow from US$ 3,495.39 million in 2022 to US$ 5,363.10 million by 2028. It is estimated to grow at a CAGR of 7.4% from 2022 to 2028.
Rising Prevalence of Immunodeficiency Diseases
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most primary immunodeficiencies (PID). Rare genetic diseases can be chronic, weakening, and expensive to treat. Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets—a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, ~200,000 ITP cases are recorded across the region annually. Thus, the increasing prevalence of immunodeficiency diseases drives the intravenous immunoglobulin market.
Market Overview
Europe is the second largest market, owing to factors such as rise in the geriatric population, increase in the prevalence of immunodeficiencies and autoimmune diseases, and high demand for the development of new therapies in the region. In addition, growing funding for research & development activities is likely to add more opportunities in the region in the coming years. The pharmaceutical industry in Germany holds the fourth largest position with small and mid-sized companies. According to the International Trade Administration (ITA), in 2019, the pharmaceutical market in Germany accounted for US$ 62.5 billion. The country is likely to remain one of the most attractive destinations for the global pharmaceutical industry in the coming years in terms of manufacturing and supply. The industry’s growth is driven by increasing investment in research and development and growing patent applications.
Local market players developing IVIg therapies are likely to favor market growth. For instance, Germany-based Biotest AG is developing polyvalent immunoglobulin preparation for intravenous administration from human plasma to treat immunodeficiencies and autoimmune diseases.
Europe Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
Europe Intravenous Immunoglobulin Market Segmentation
The Europe intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.
Based on application, the Europe intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022.
Based on distribution channel, the Europe intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022.
Based on end user, the Europe intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022.
Based on country, the market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the market in 2022.
ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Europe Intravenous Immunoglobulin Market – By Type
1.3.2 Europe Intravenous Immunoglobulin Market – By Application
1.3.3 Europe Intravenous Immunoglobulin Market – By Distribution Channel
1.3.4 Europe Intravenous Immunoglobulin Market – By End User
1.3.5 Europe Intravenous Immunoglobulin Market – By Country
2. Europe Intravenous Immunoglobulin Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Intravenous Immunoglobulin Market – Market Landscape
4.1 Overview
4.2 Europe PEST Analysis
4.3 Expert Opinion
5. Europe Intravenous Immunoglobulin Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Immunodeficiency Diseases
5.1.2 Increasing Geriatric Population
5.2 Market Restraints
5.2.1 Adverse Effects of Immunoglobulin Therapy
5.3 Future Trends
5.3.1 Strong Pipeline Candidates for IVIG
5.4 Impact Analysis
6. Intravenous Immunoglobulin Market– Europe Analysis
6.1 Europe Intravenous Immunoglobulin Market Revenue Forecast and Analysis
7. Europe Intravenous Immunoglobulin Market Revenue and Forecast to 2028– by Type
7.1 Overview
7.2 Europe Intravenous Immunoglobulin Market, By Type 2022 & 2028 (%)
7.3 IgG
7.3.1 Overview
7.3.2 IgG Revenue and Forecast to 2028 (US$ Million)
7.4 IgM
7.4.1 Overview
7.4.2 IgM – Revenue and Forecast to 2028 (US$ Million)
7.5 IgA
7.5.1 Overview
7.5.2 IgA – Revenue and Forecast to 2028 (US$ Million)
7.6 IgE
7.6.1 Overview
7.6.2 IgE – Revenue and Forecast to 2028 (US$ Million)
7.7 IgD
7.7.1 Overview
7.7.2 IgD – Revenue and Forecast to 2028 (US$ Million)
8. Europe Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Application
8.1 Overview
8.2 Europe Intravenous Immunoglobulin Market, By Application 2022 & 2028 (%)
8.3 Hypogammaglobulinemia
8.3.1 Overview
8.3.2 Hypogammaglobulinemia – Market Revenue and Forecast to 2028 (US$ Million)
8.4 Chronic Inflammatory Demyelinating Polyneuropathy
8.4.1 Overview
8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy – Market Revenue and Forecast to 2028 (US$ Million)
8.5 Immunodeficiency Diseases
8.5.1 Overview
8.5.2 Immunodeficiency Diseases – Market Revenue and Forecast to 2028 (US$ Million)
8.6 Myasthenia Gravis
8.6.1 Overview
8.6.2 Myasthenia Gravis – Market Revenue and Forecast to 2028 (US$ Million)
8.7 Multifocal Motor Neuropathy
8.7.1 Overview
8.7.2 Multifocal Motor Neuropathy – Market Revenue and Forecast to 2028 (US$ Million)
8.8 Idiopathic Thrombocytopenic Purpura
8.8.1 Overview
8.8.2 Idiopathic Thrombocytopenic Purpura – Market Revenue and Forecast to 2028 (US$ Million)
8.9 Inflammatory Myopathies
8.9.1 Overview
8.9.2 Inflammatory Myopathies – Market Revenue and Forecast to 2028 (US$ Million)
8.10 Specific Antibody Deficiency
8.10.1 Overview
8.10.2 Specific Antibody Deficiency – Market Revenue and Forecast to 2028 (US$ Million)
8.11 Guillain-Barre Syndrome
8.11.1 Overview
8.11.2 Guillain-Barre Syndrome – Market Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Others – Market Revenue and Forecast to 2028 (US$ Million)
9. Europe Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Distribution Channel
9.1 Overview
9.2 Europe Intravenous Immunoglobulin Market, By Distribution Channel 2022 & 2028 (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy – Market Revenue and Forecast to 2028 (US$ Million)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy – Market Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others – Market Revenue and Forecast to 2028 (US$ Million)
10. Europe Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by End User
10.1 Overview
10.2 Europe Intravenous Immunoglobulin Market, By End User 2022 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals – Market Revenue And Forecasts To 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics – Market Revenue And Forecasts To 2028 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others – Market Revenue And Forecasts To 2028 (US$ Million)
11. Europe Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 – Country Analysis
11.1 Overview
11.1.1 Europe: Intravenous Immunoglobulin Market, by Country, 2022 & 2028 (%)
11.1.1.1 UK: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 UK: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.1.3 UK: Intravenous Immunoglobulin Market, by Type, 2019–2028 (US$ Million)
11.1.1.1.4 UK: Intravenous Immunoglobulin Market, by Application, 2019–2028 (US$ Million)
11.1.1.1.5 UK: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.1.6 UK: Intravenous Immunoglobulin Market, by End User, 2019–2028 (US$ Million)
11.1.1.2 Germany: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Germany: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.2.3 Germany: Intravenous Immunoglobulin Market, by Type, 2019–2028 (US$ Million)
11.1.1.2.4 Germany: Intravenous Immunoglobulin Market, by Application, 2019–2028 (US$ Million)
11.1.1.2.5 Germany: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.2.6 Germany: Intravenous Immunoglobulin Market, by End User, 2019–2028 (US$ Million)
11.1.1.3 France: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 France: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.3.3 France: Intravenous Immunoglobulin Market, by Type, 2019–2028 (US$ Million)
11.1.1.3.4 France: Intravenous Immunoglobulin Market, by Application, 2019–2028 (US$ Million)
11.1.1.3.5 France: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.3.6 France: Intravenous Immunoglobulin Market, by End User, 2019–2028 (US$ Million)
11.1.1.4 Italy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.1 Overview
11.1.1.4.2 Italy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.4.3 Italy: Intravenous Immunoglobulin Market, by Type, 2019–2028 (US$ Million)
11.1.1.4.4 Italy: Intravenous Immunoglobulin Market, by Application, 2019–2028 (US$ Million)
11.1.1.4.5 Italy: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.4.6 Italy: Intravenous Immunoglobulin Market, by End User, 2019–2028 (US$ Million)
11.1.1.5 Spain: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.5.1 Overview
11.1.1.5.2 Spain: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.5.3 Spain: Intravenous Immunoglobulin Market, by Type, 2019–2028 (US$ Million)
11.1.1.5.4 Spain: Intravenous Immunoglobulin Market, by Application, 2019–2028 (US$ Million)
11.1.1.5.5 Spain: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.5.6 Spain: Intravenous Immunoglobulin Market, by End User, 2019–2028 (US$ Million)
11.1.1.6 Rest of Europe: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Europe: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
11.1.1.6.3 Rest of Europe: Intravenous Immunoglobulin Market, by Type, 2019–2028 (US$ Million)
11.1.1.6.4 Rest of Europe: Intravenous Immunoglobulin Market, by Application, 2019–2028 (US$ Million)
11.1.1.6.5 Rest of Europe: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (US$ Million)
11.1.1.6.6 Rest of Europe: Intravenous Immunoglobulin Market, by End User, 2019–2028 (US$ Million)
12. Europe Intravenous Immunoglobulin Market–Industry Landscape
12.1 Overview
12.2 Inorganic Growth Strategies
12.2.1 Overview
12.3 Organic Growth Strategies
12.3.1 Overview
13. Company Profiles
13.1 Takeda Pharmaceutical Company Limited
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Grifols, S.A.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bio Products Laboratory Ltd.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Shanghai RAAS
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Octapharma AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Kedrion S.p.A
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CSL Behring (CSL Limited)
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Prothya Biosolutions B.V.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms in Intravenous Immunoglobulin Market
Table 1. Europe Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
Table 2. UK Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. UK: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 4. UK Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 5. UK Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 6. Germany Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 7. Germany: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 8. Germany Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 9. Germany Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 10. France Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 11. France: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 12. France Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 13. France Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 14. Italy Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. Italy: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 16. Italy Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 17. Italy Intravenous Immunoglobulin Market, by End User – Revenue and Forecast to 2028 (US$ Million)
Table 18. Spain Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 19. Spain: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 20. Spain Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 21. Spain Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 22. Rest of Europe Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of Europe: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (US$ Million)
Table 24. Rest of Europe Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (US$ Million)
Table 25. Rest of Europe Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (US$ Million)
Table 26. Recent Inorganic Growth Strategies in the Intravenous Immunoglobulin Market
Table 27. Recent Organic Growth Strategies in the Intravenous Immunoglobulin Market
Table 28. Glossary of Terms in Intravenous Immunoglobulin Market
Figure 1. Europe Intravenous Immunoglobulin Market Segmentation
Figure 2. Europe Intravenous Immunoglobulin Market Segmentation, By Country
Figure 3. Europe Intravenous Immunoglobulin Market Overview
Figure 4. Europe Intravenous Immunoglobulin Market, by Type
Figure 5. Europe Intravenous Immunoglobulin Market, by Country
Figure 6. Europe: PEST Analysis
Figure 7. Impact Analysis
Figure 8. Europe Intravenous Immunoglobulin Market– Revenue Forecast and Analysis – 2020 – 2028
Figure 9. Europe Intravenous Immunoglobulin Market, by Type 2022 & 2028 (%)
Figure 10. Europe IgG Revenue and Forecasts to 2028 (US$ Million)
Figure 11. Europe IgM – Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Europe IgA – Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Europe IgE – Revenue and Forecasts to 2028 (US$ Million)
Figure 14. Europe IgD – Revenue and Forecasts to 2028 (US$ Million)
Figure 15. Europe Intravenous Immunoglobulin Market, by Application 2022 & 2028 (%)
Figure 16. Europe Hypogammaglobulinemia – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. Europe Chronic Inflammatory Demyelinating Polyneuropathy – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. Europe Immunodeficiency Diseases – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Europe Myasthenia Gravis – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Europe Multifocal Motor Neuropathy – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Europe Idiopathic Thrombocytopenic Purpura – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Europe Inflammatory Myopathies – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Europe Specific Antibody Deficiency – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. Europe Guillain-Barre Syndrome – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. Europe Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. Europe Intravenous Immunoglobulin Market, by Distribution Channel 2022 & 2028 (%)
Figure 27. Europe Hospital Pharmacy – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. Europe Retail Pharmacy – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. Europe Others – Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. Europe Intravenous Immunoglobulin Market, by End User 2022 & 2028 (%)
Figure 31. Europe Hospitals – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 32. Europe Specialty Clinics – Market Revenue And Forecasts To 2028 (US$ Million)
Figure 33. Europe Others- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 34. Europe: Intravenous Immunoglobulin Market, by Key Country – Revenue (2022) (US$ Million)
Figure 35. Europe: Intravenous Immunoglobulin Market, by Country, 2022 & 2028 (%)
Figure 36. UK: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. Germany: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. France: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 39. Italy: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 40. Spain: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 41. Rest of Europe: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe intravenous immunoglobulin market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the Europe intravenous immunoglobulin market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the intravenous immunoglobulin market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution
● ADMA Biologics, Inc.
● Bio Products Laboratory Ltd.
● CSL Behring (CSL Limited)
● Grifols, S.A.
● Kedrion S.p.A
● Octapharma AG
● Pfizer Inc.
● Prothya Biosolutions B.V.
● Shanghai RAAS
● Takeda Pharmaceutical Company Limited
At 7.4% CAGR, the Europe Intravenous Immunoglobulin Market is speculated to be worth US$ 5,363.10 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the Europe intravenous immunoglobulin market was valued at US$ 3,495.39 million in 2022 and is expected to reach US$ 5,363.10 million by 2028, registering a CAGR of 7.4% from 2022 to 2028. Increasing geriatric population and rising prevalence of immunodeficiency diseases are the critical factors attributed to the market expansion.
As per the Eurostat, in 2019, there were around 90.4 million older people (aged 65 years or above) living in the EU-27. As per the United Nations Population Division, World Population Prospects 2019, Asian and European countries have some of the world’s oldest populations aged 65 and more. Japan being at top with 28%, followed by Italy at 23%. Further, Finland, Portugal, and Greece are among the top five countries with aged population under 22%. Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person’s body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve use of IVIg. Thus, the increase in geriatric population across the region is bolstering the intravenous immunoglobulin market.
On the contrary, adverse effects of immunoglobulin therapy hurdles the growth of Europe intravenous immunoglobulin market.
Based on type, the Europe intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment held 28.8% market share in 2022, amassing US$ 1,005.64 million. It is projected to garner US$ 1,532.26 million by 2028 to expand at 7.3% CAGR during 2022–2028. Based on application, the Europe intravenous immunoglobulin market is segmented hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment held 21.6% market share in 2022, amassing US$ 755.53 million. It is projected to garner US$ 1,196.92 million by 2028 to expand at 8.0% CAGR during 2022–2028. Based on distribution channel, the Europe intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held 55.8% market share in 2022, amassing US$ 1,949.51 million. It is projected to garner US$ 2,968.11 million by 2028 to expand at 7.3% CAGR during 2022–2028. Based on end user, the Europe intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The beverages segment held 47.6% market share in 2022, amassing US$ 1,662.23 million. It is projected to garner US$ 2,514.16 million by 2028 to expand at 7.1% CAGR during 2022–2028. Based on country, the Europe intravenous immunoglobulin market is segmented into Germany, UK, France, Italy, Spain, and Rest of Europe. Our regional analysis states that Germany captured 26.6% market share in 2022. It was assessed at US$ 929.22 million in 2022 and is likely to hit US$ 1,440.72 million by 2028, exhibiting a CAGR of 7.6% during the forecast period.
Key players dominating the Europe intravenous immunoglobulin market are ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited among others.
In 2022, BPL and Atlantic Research Group entered into long-term collaboration. This agreement establishes ARG as BPL’s preferred contract research organization (CRO) for conducting clinical research trials and providing supportive services for the company’s global new product development programs. The agreement builds on BPL and ARG’s previous successful collaboration on clinical trial programs.
In 2021, Grifols began a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.
Related Reports
- $3,000.00 – $5,000.00
